Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth

This article was originally published in The Gray Sheet

Executive Summary

“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.

Advertisement

Related Content

HeartWare Touts Early Success In U.S. Launch Of HVAD
Pressure Builds In Ventricular Assist Market
Study In Circulation Questions Cost Effectiveness Of VADs
Thoratec Takes Over REVIVE-IT LVAD Trial From HeartWare
FDA Sticks Newly Approved HeartWare VAD With Unexpected Labeling Requirement
Thoratec Downplays Threats From Competing HeartWare Pump
Thoratec Expands Circulatory Support Biz With Levitronix Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032713

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel